APRI (Aprinoia Therapeutics) Pretax Margin %: -58,851.43% (As of Dec. 2023)


What is Aprinoia Therapeutics Pretax Margin %?

Aprinoia Therapeutics APRI Pretax Margin % is -58,851.43% as of Dec. 2023.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Aprinoia Therapeutics's Pre-Tax Income for the six months ended in Dec. 2023 was $-20.60 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Therefore, Aprinoia Therapeutics's pretax margin for the quarter that ended in Dec. 2023 was -58,851.43%.

The historical rank and industry rank for Aprinoia Therapeutics's Pretax Margin % or its related term are showing as below:


APRI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63
* Ranked among companies with meaningful Pretax Margin % only.

Aprinoia Therapeutics  (NAS:APRI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Aprinoia Therapeutics Pretax Margin % Related Terms

Aprinoia Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Pretax Margin % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Pretax Margin %
-4,229.27 -7,160.91 -305.77

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Pretax Margin % 0.00 -4,633.90 -14,690.91 -78.95 -58,851.43

APRI vs : Pretax Margin % Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Pretax Margin % falls into.


Aprinoia Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-27.73/9.069
=-305.77 %

Aprinoia Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-20.598/0.035
=-58,851.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -58,851.43% mean?
Aprinoia Therapeutics (APRI) has a Pretax Margin % of -58,851.43% as of Dec. 2023. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Pretax Margin % too high?
Aprinoia Therapeutics' current Pretax Margin % is -58,851.43%.
How does Aprinoia Therapeutics' Pretax Margin % compare to ?
Aprinoia Therapeutics' Pretax Margin % of -58,851.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Pretax Margin % is -58,851.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Pretax Margin % of -58,851.43%. The current Pretax Margin % is -58,851.43%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Pretax Margin % is -58,851.43% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.